Loss or inhibition of CCR2 is known to significantly reduce levels of circulating monocytes and, as a result, numbers of bone marrow–derived TAMs (20, 33), and reducing TAMs may be beneficial as a therapeutic strategy against PDA (e.g., 14, 17, 18, 34). This evidence concerns the gene CCR2 and Patent ductus arteriosus.